The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...

Zilbermint highlights Lantus (insulin glargine ... the insulin maker plans to discontinue U.S. sales of the FlexPen version of Levemir in April 2024 and Levemir vials by the end of December.

If insulin glargine was prescribed ... a sole insulin analogue that could not be substituted with Innolet or FlexPen. Outcomes measures. Patient satisfaction. All patients completed a self ...

long-acting insulin substitutes." Last November, Novo Nordisk announced it would stop selling the injectable FlexPen version of Levemir this month and halt sales of Levemir vials by December 2024.